CEBPA MUTATION ANALYSIS

General Information

HLAB/HOL Code: FCEMA
UPHSM LIS Test #: 6839
Schedule:
Testing Time:
Testing Lab: Labcorp

Specimen Info
Only 1 specimen type required, unless otherwise specified

Volume: 3-5 mL
Temperature: Ambient
Tube Type: EDTA Whole Blood
Collection Info:
Green-top (sodium heparin) tube is also acceptable

Volume: 1-2 mL
Temperature: Ambient
Tube Type: EDTA Bone Marrow
Collection Info:
Green-top (sodium heparin) tube is also acceptable

Methods

Polymerase chain reaction (PCR); direct sequencing; capillary electrophoresis

Clinical Utilities

The CEBPA (CCAAT/enhancer binding protein α) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6% to 15% of de novo acute myeloid leukemia (AML) and in 15% to 18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.

CPT Codes

81218

* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Reference Range

An interpretive report will be sent.